Background: We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response. Methods: She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021. In April 2021 she received the first dose of mRNA BNT162b2 vaccine. Ten days later she developed myalgia, dyspnea and numbness of the limbs due to a relapse of EGPA that occurred during Mepolizumab treatment.
Eosinophilic granulomatosis with polyangiitis relapse after covid-19 vaccination: A case report
Costanzo G.
;Ledda A. G.;Ghisu A.;Vacca M.;Firinu D.;Del Giacco S.
2022-01-01
Abstract
Background: We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response. Methods: She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021. In April 2021 she received the first dose of mRNA BNT162b2 vaccine. Ten days later she developed myalgia, dyspnea and numbness of the limbs due to a relapse of EGPA that occurred during Mepolizumab treatment.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
vaccines-10-00013-v2 Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination.pdf
accesso aperto
Tipologia:
versione editoriale
Dimensione
286.88 kB
Formato
Adobe PDF
|
286.88 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
